CDK4/6 Inhibition on Glucose and Pancreatic Beta Cell Homeostasis in Young and Aged Rats

Genetic deletion of cyclin-dependent kinase 4 (Cdk4) is associated with pancreatic beta cell loss and glucose dysregulation in rodents. Palbociclib, one of the first selective CDK4/6 inhibitors approved for the treatment of advanced breast cancer, is currently being investigated as an adjuvant treatment in patients with early-stage breast cancer and in a variety of cancers covering a wide-range of patient populations. Hence, longer chronic toxicity studies were necessary to further examine its safety profile. The effects of different doses and duration of palbociclib administration on glucose and beta cell homeostasis in young (two months) versus aged (12 months) rats was compared. Glucose dysregulation, due to pancreatic beta cell degeneration, was observed in young rats administered the highest dose of palbociclib for 6 months. Abnormal pancreatic islet histology and activation of the endoplasmic reticulum stress response in beta cells were detected after shorter administration with high-dose palbociclib in young rats. To test the hypothesis that palbociclib-associated inhibition of beta cell proliferation will more profoundly affect younger animals that have not achieved replicative quiescence, we administered high-dose palbociclib to aged rats for 6 months. In contrast to the young rats, despite equivalent exposures to palbociclib, no evidence of impaired glucose tolerance, hypoinsulinemia, beta cell vacuolization, or beta cell loss was seen in aged rats. Palbociclib administration induces beta cell failure in young but not aged rats. Implications: Although adult humans receiving palbociclib have not displayed detectable adverse effects on glucose metabolism, the risk of beta cell failure in children remains unexplored. Mol Cancer Res; 15(11); 1531–41. ©2017 AACR.

[1]  K. Gelmon,et al.  Palbociclib and Letrozole in Advanced Breast Cancer. , 2016, The New England journal of medicine.

[2]  E. Winer,et al.  Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. , 2016, The New England journal of medicine.

[3]  S. Loi,et al.  Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). , 2016, The oncologist.

[4]  K. Kaestner,et al.  Effects of ageing and senescence on pancreatic β‐cell function , 2016, Diabetes, obesity & metabolism.

[5]  A. F. Stewart,et al.  Parathyroid Hormone-Related Peptide (1-36) Enhances Beta Cell Regeneration and Increases Beta Cell Mass in a Mouse Model of Partial Pancreatectomy , 2016, PloS one.

[6]  Tuan S. Nguyen,et al.  Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors. , 2016, Cancer discovery.

[7]  G. Shapiro,et al.  Targeting CDK4 and CDK6: From Discovery to Therapy. , 2016, Cancer discovery.

[8]  M. Malumbres,et al.  Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases , 2016, Nature Reviews Molecular Cell Biology.

[9]  A. Klochendler,et al.  p16Ink4a-induced senescence of pancreatic beta cells enhances insulin secretion , 2016, Nature Medicine.

[10]  C. Kahn,et al.  CDK4 is an essential insulin effector in adipocytes. , 2016, The Journal of clinical investigation.

[11]  Michael B. Stadler,et al.  Aging-Dependent Demethylation of Regulatory Elements Correlates with Chromatin State and Improved β Cell Function. , 2015, Cell metabolism.

[12]  U. Rix,et al.  Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer. , 2015, ACS chemical biology.

[13]  S. Loi,et al.  Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. , 2015, The New England journal of medicine.

[14]  J. Penninger,et al.  Osteoprotegerin and Denosumab Stimulate Human Beta Cell Proliferation through Inhibition of the Receptor Activator of NF-κB Ligand Pathway. , 2015, Cell metabolism.

[15]  L. Fajas,et al.  Cell cycle regulation of mitochondrial function. , 2015, Current opinion in cell biology.

[16]  P. Wang,et al.  Diabetes mellitus—advances and challenges in human β-cell proliferation , 2015, Nature Reviews Endocrinology.

[17]  S. Devarakonda,et al.  Cyclin D1 Represses Gluconeogenesis via Inhibition of the Transcriptional Coactivator PGC1α , 2014, Diabetes.

[18]  P. Puigserver,et al.  Cyclin D1-CDK4 Controls Glucose Metabolism Independently of Cell Cycle Progression , 2014, Nature.

[19]  Y. Choi,et al.  Signaling through cyclin D-dependent kinases , 2014, Oncogene.

[20]  R. Pestell,et al.  Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present , 2014, Expert opinion on investigational drugs.

[21]  Amy E. Cox,et al.  Human Pancreatic β-Cell G1/S Molecule Cell Cycle Atlas , 2013, Diabetes.

[22]  F. R. Papa,et al.  Endoplasmic reticulum stress, pancreatic β-cell degeneration, and diabetes. , 2012, Cold Spring Harbor perspectives in medicine.

[23]  N. Inagaki,et al.  Role of sodium‐glucose transporters in glucose uptake of the intestine and kidney , 2012, Journal of diabetes investigation.

[24]  M. Atkinson,et al.  Formation of a human β-cell population within pancreatic islets is set early in life. , 2012, The Journal of clinical endocrinology and metabolism.

[25]  E. Hanse,et al.  Cyclin D1 inhibits hepatic lipogenesis via repression of carbohydrate response element binding protein and hepatocyte nuclear factor 4α , 2012, Cell cycle.

[26]  J. Cicenas,et al.  The CDK inhibitors in cancer research and therapy , 2011, Journal of Cancer Research and Clinical Oncology.

[27]  C. Sardet,et al.  The CDK4–pRB–E2F1 pathway controls insulin secretion , 2009, Nature Cell Biology.

[28]  Lillian L. Siu,et al.  Cyclin-dependent kinase inhibitors as potential targeted anticancer agents , 2009, Investigational New Drugs.

[29]  T. Gurlo,et al.  Age-Dependent Decline in β-Cell Proliferation Restricts the Capacity of β-Cell Regeneration in Mice , 2009, Diabetes.

[30]  A. F. Stewart,et al.  Molecular Control of Cell Cycle Progression in the Pancreatic β-Cell , 2006 .

[31]  J. Kushner,et al.  Very Slow Turnover of β-Cells in Aged Adult Mice , 2005 .

[32]  Ana Maria Cuervo,et al.  Autophagy and Aging: The Importance of Maintaining "Clean" Cells , 2005, Autophagy.

[33]  D. W. Fry,et al.  Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. , 2005, Journal of medicinal chemistry.

[34]  Senta Georgia,et al.  β cell replication is the primary mechanism for maintaining postnatal β cell mass , 2004 .

[35]  M. Barbacid,et al.  Genetic rescue of Cdk4 null mice restores pancreatic β-cell proliferation but not homeostatic cell number , 2003, Oncogene.

[36]  M. Barbacid,et al.  Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in β-islet cell hyperplasia , 1999, Nature Genetics.

[37]  S. Munro,et al.  A C-terminal signal prevents secretion of luminal ER proteins , 1987, Cell.

[38]  Ich Harmonised,et al.  INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED GUIDELINE GENERAL CONSIDERATIONS FOR CLINICAL STUDIES E8(R1) , 2019 .

[39]  Xin Huang,et al.  The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. , 2015, The Lancet. Oncology.

[40]  T. Gurlo,et al.  Age-dependent Decline in Beta Cell Proliferation Restricts the Capacity of Beta Cell Regeneration in Mice , 2009 .

[41]  A. F. Stewart,et al.  Molecular control of cell cycle progression in the pancreatic beta-cell. , 2006, Endocrine reviews.

[42]  A. F. Stewart,et al.  Evaluation of beta-cell replication in mice transgenic for hepatocyte growth factor and placental lactogen: comprehensive characterization of the G1/S regulatory proteins reveals unique involvement of p21cip. , 2006, Diabetes.

[43]  J. Kushner,et al.  Very slow turnover of beta-cells in aged adult mice. , 2005, Diabetes.

[44]  Senta Georgia,et al.  Beta cell replication is the primary mechanism for maintaining postnatal beta cell mass. , 2004, The Journal of clinical investigation.

[45]  Yuval Dor,et al.  Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. , 2004, Nature.